Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Klaria Pharma Holding

0,49

 

SEK

 

+13,95 %

Mindre end 1K følgere

KLAR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
+13,95%
+21,71%
-58,63%
+67,56%
+50,05%
+57,09%
-86,66%
-84,86%
-89,28%

Klaria Pharma Holding operates in the pharmaceutical industry. The business is focused on developing and commercializing solutions in the therapy areas of migraine and cancer-related pain. The technology is based on the company's drug-delivery platform, where the product consists of the alginate-based polymer film. The film attaches to the patient's oral mucosa, which enables the distribution of pharmaceuticals in the body. The head office is located in Uppsala.

Læs mere
Markedsværdi
150,73 mio. SEK
Aktieomsætning
469,68 t SEK
Omsætning
2,25 mio.
EBIT %
-1.387,11 %
P/E
-
Udbytteafkast, %
-
Finanskalender
28.8
2025

Delårsrapport Q2'25

26.11
2025

Delårsrapport Q3'25

20.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse3.7.2025, 08.30

Klaria Pharma Holding AB: Klaria stengthens patent portfolio of sumatriptan alginate film with new filing

Klaria Pharma Holding
Selskabsmeddelelse21.5.2025, 14.16

Klaria Pharma Holding AB: Klaria Interim Report

Klaria Pharma Holding
Selskabsmeddelelse30.4.2025, 09.00

Klaria Pharma Holding AB: Klaria Annual Report 2024

Klaria Pharma Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Pressemeddelelse28.2.2025, 16.38

Redeye: Klaria Pharma Q4 - Transforming licensing deal

Klaria Pharma Holding
Selskabsmeddelelse28.2.2025, 09.10

Klaria Pharma Holding AB: Klaria Year-End Report 2024

Klaria Pharma Holding
Pressemeddelelse15.1.2025, 07.41

Redeye: Klaria Pharma - Licensing deal with CNX Therapeutic

Klaria Pharma Holding
Selskabsmeddelelse10.1.2025, 18.00

Klaria Pharma Holding AB: Klaria signs license agreement for Sumatriptan Alginate film in Europe with CNX Therapeutics

Klaria Pharma Holding
Pressemeddelelse22.11.2024, 09.24

Redeye: Klaria Pharma Q3 - Awaiting business developments

Klaria Pharma Holding
Selskabsmeddelelse21.11.2024, 14.00

Klaria Pharma Holding AB: Klaria Interim Report Q3 2024

Klaria Pharma Holding
Pressemeddelelse23.8.2024, 06.35

Redeye: Klaria Pharma Q2 - Defining Chapter Approaches

Klaria Pharma Holding
Selskabsmeddelelse22.8.2024, 14.00

Klaria Pharma Holding AB: Klaria Interim Report Q2 2024

Klaria Pharma Holding
Selskabsmeddelelse14.8.2024, 06.30

Klaria Pharma Holding AB: Klaria Sumatriptan Alginate Film Receives Marketing Authorization

Klaria Pharma Holding
Pressemeddelelse17.5.2024, 05.48

Redeye: Klaria Pharma Q1 - Crucial period ahead

Klaria Pharma Holding
Selskabsmeddelelse16.5.2024, 09.37

Klaria Pharma Holding AB: Klaria Interim Report Q1 2024

Klaria Pharma Holding
Pressemeddelelse1.3.2024, 15.00

Redeye: Klaria Pharma Q4 - Eyes on the prize

Klaria Pharma Holding
Selskabsmeddelelse29.2.2024, 15.30

Klaria Pharma Holding AB: Klaria Year-End Report 2023

Klaria Pharma Holding
Selskabsmeddelelse26.2.2024, 11.27

Klaria Pharma Holding AB: Klaria accelerates its business development efforts

Klaria Pharma Holding
Pressemeddelelse27.11.2023, 07.19

Redeye: Klaria Pharma Q3 2023 - Take-off is on the horizon

Klaria Pharma Holding
Selskabsmeddelelse24.11.2023, 13.30

Klaria Pharma Holding AB: Klaria Interim Report Q3 2023

Klaria Pharma Holding
Selskabsmeddelelse25.10.2023, 14.28

Klaria Pharma Holding AB: Klaria's board of directors announces that CEO Jesper Wiklund leaves the company

Klaria Pharma Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.